| Literature DB >> 11025878 |
S Takasu1, T Wakabayashi, Y Kajita, N Hatano, H Hatano, T Usui, T Kinoshita, J Yoshida.
Abstract
Six cases with recurrent or refractory primary central nervous system lymphoma were treated with a new chemotherapeutic regimen "DeVIC (dexamethasone, VP16, ifosfamide, carboplatin)". Five recurrent cases had a remission period for an average of 18 months after initial treatment, but relapse occurred. One refractory case had no response after initial treatment. Then these 6 cases were treated with 1-3 courses of DeVIC chemotherapy at intervals of 4 weeks. Two cases achieved complete remission, and 3 cases attained partial remission (response rate was 83%). One case showed no response after 1 course of DeVIC chemotherapy. However, in all cases re-relapse occurred 1-5 months after remission, and only 1 case is still alive. DeVIC chemotherapy produced a high response rate for recurrent central nervous system lymphoma, but re-relapse occurred after only a few months. The establishment of maintenance chemotherapy is required.Entities:
Mesh:
Substances:
Year: 2000 PMID: 11025878
Source DB: PubMed Journal: No Shinkei Geka ISSN: 0301-2603